Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients. [PDF]
Liu X +5 more
europepmc +1 more source
Collagen IV immunohistochemistry and autoimmune bullous diseases: defining the location of the subepidermal bullae. [PDF]
Nieto-Benito LM +2 more
europepmc +1 more source
Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. [PDF]
Kasperkiewicz M +9 more
europepmc +1 more source
Uncommon and Unusual Variants of Autoimmune Bullous Diseases. [PDF]
Kiran, Rao R.
europepmc +1 more source
COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation. [PDF]
Kasperkiewicz M +5 more
europepmc +1 more source
Scoring Criteria for Autoimmune Bullous Diseases: Utility, Merits, and Demerits. [PDF]
Tseng H, Stone C, Murrell DF.
europepmc +1 more source
Epidemiological Insights into Autoimmune Bullous Diseases in China: A Comprehensive Analysis. [PDF]
Chen Z +17 more
europepmc +1 more source
Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study. [PDF]
Mahmoudi H +11 more
europepmc +1 more source
A retrospective analysis of oral autoimmune bullous diseases at a Thai oral medicine center. [PDF]
Sakdapreecha C, Kanjanabuch P.
europepmc +1 more source
COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases. [PDF]
Kasperkiewicz M.
europepmc +1 more source

